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1. Introduction 
Coagulation is a complex physiological balancing mechanism that maintains haemostasis 
when blood vessels are injured. A hypercoaguable state as seen in early sepsis, cancer or 
pregnancy can cause arterial and/or venous obstruction with disruption of blood-flow and 
end organ damage. Similarly a hypocoaguable state can cause catastrophic haemorrhage 
and lead to death.  
Up to 20% of all blood transfusions in the USA are related to cardiac surgery (1). The 
pathogenesis of coagulopathy in this patient group is multifactorial: patients are older (2), and 
more complex and this is reflected in the number of redo surgeries and the concomitant use of 
agents such as clopidogrel, aspirin, coumarin anticoagulants and heparins. Also 
cardiopulmonary bypass activates the coagulation system with an initial hypercoaguable state 
and platelet activation, followed by factor and platelet consumption. Hypothermia, acidosis, 
hypocalcaemia and the dilutional effects of circuit priming all increase the risk of bleeding (3).  
Platelet transfusion per se in the perioperative period has been associated with an increased 
risk of serious adverse events (4). Indeed both red cell and platelet transfusion have been 
shown to have a negative risk-adjusted effect on health-related quality of life after cardiac 
surgery (5). The haemostatic status of a patient undergoing cardiopulmonary bypass can 
change very quickly because of haemorrhage or the use of high dose heparin or protamine 
and as such blood component administration in cardiac surgery can often be empiric. This is 
compounded by the limited utility of the standard coagulation tests, which have a slow 
turnaround time in a setting where there can be rapid changes in coagulation status.  
All patients presenting for cardiac surgery will be anticoagulated in the perioperative 
period, either for cardiac or non-cardiac reasons, and an appropriate balance needs to be 
struck between minimising perioperative blood loss and use of homologous blood products, 
and avoiding pathological thrombosis.  
Coagulation status can be measured by means of laboratory tests or near-patient tests (also 
referred to as point-of-care tests). Effective use and interpretation of these tests can guide 
physicians and surgeons alike in the use of medications and homologous blood products 
and timely intervention of surgery to optimise patient outcomes. Indeed, the 
thromboelastogram (TEG), a point-of-care test, should discriminate “surgical” from 
“medical” causes of bleeding in this population thus reducing unnecessary transfusions and 
allowing timely return to the operating room for definitive treatment. The TEG will also 
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Perioperative Considerations in Cardiac Surgery 180 
facilitate targeted therapy in a “medically” bleeding patient by providing information about 
platelet function and degree of fibrinolysis as well as factors produced in the liver. Standard 
coagulation tests and point-of-care tests will be discussed in detail with reference to their 
individual utility in this group of patients. 
2. Coagulation pathways 
Coagulation requires complex interactions of cellular and molecular components, mainly 
involving platelets, plasma and red blood cells. The process was classically described as a 
cascade of ‘Intrinsic’, ‘Extrinsic’, and ‘Common’ pathways (see Figure 1). These pathways  
 
 
The Intrinsic Pathway is activated when FXII binds to exposed collagen of damaged endothelium. The 
cascade of activations occur as shown, and amplification also occurs (for example FXIIa converts 
prekallikrien to kallikrien and auto-activates more FXII). The resulting “Tenase” complex (shown in a 
dashed yellow line) activates FX. The Extrinsic Pathway is initiated by Tissue Factor, and results in a 
TF/FVIIa complex (in a dashed yellow line) that activates FX. The Common Pathway yields thrombin 
(FIIa), which not only activates Fibrinogen (FI) but also amplifies other stages of the cascade by 
activating FVIII, FV and FXIII. The ultimate result is a cross-linked Fibrin mesh. HMWK = High 
Molecular Weight Kininogen. PL = Phospholipid. 
Fig. 1. The Classic Coagulation Cascade Model(6).  
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are useful in terms of interpreting some of the coagulation tests, but in vitro coagulation is 
less linear and occurs by a combination of these pathways. Current understanding of the 
coagulation process is best described by the cell-based model. 
The coagulation factors were discovered in the 1940s and 1950s. They are proenzymes found 
in plasma, which are converted to active enzymes during the coagulation process. The 
factors were assigned roman numerals in the order they were discovered; each factor also 
has one or more names. The more commonly used ones are shown in the figure 2 (6). The 
numerals are prefixed by “F” for “factor”, and the suffix “a” is used to indicate the activated 
form of the factor. 
 
I  Fibrinogen 
II  Prothrombin 
IIa Thrombin 
III Tissue Factor / Tissue Thromboplastin (sometimes excluded from the list of factors - 
not actually a plasma proenzyme, but an integral membrane protein, which is a 
receptor for FVII) 
IV Calcium ions 
V  Labile Factor / Proaccelerin / accelerator (AC-) globulin 
VI Factor Va was once known as FVI 
VII  Serum Factor / Stable Factor / Proconvertin / Serum Prothrombin Conversion 
Accelerator (SPCA) / Cothromboplastin / Autoprothrombin I 
VIII  Haemophilia A factor / antihaemophiliac Factor / Plasma Thromboplastic Factor / 
Thromboplastinogen / Platelet Cofactor 
IX  Haemophilia B Factor / Christmas Factor / Plasma Thromboplastin Component  
X   
XI  Haemophilia C factor / Plasma Thromboplastin Antecedent (PTA) 
XII  Hageman Factor / Contact Factor 
XIII  Fibrin Stabilizing Factor  
Fig. 2. Factor Numbers and Common name(s) – anomalies are shown in green 
3. Intrinsic pathway 
The “Intrinsic Pathway”, so-called because its components are all present within whole 
blood, is initiated when blood comes in contact with a negatively charged surface such as 
glass or the surface of an activated platelet. It consists of a reaction cascade involving FXII, 
High Molecular Weight Kininogen (HMWK), prekallikrien, FXI, FIX, FIIa, FVIII, and Ca2+ 
and culminates in the activation of FX at the Common Pathway. The activated partial 
thromboplastin time (APTT) laboratory test measures the intrinsic pathway. 
4. Extrinsic pathway 
The “Extrinsic Pathway” is initiated when endothelial injury causes tissue factor (TF, or FIII) 
to come into contact with FVII. TF non-proteolytically activates FVII. The FVIIa/TF complex 
then activates FX. The extrinsic pathway can be measured by the Prothrombin Time (PT) 
laboratory test. 
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5. The common pathway 
The intrinsic and extrinsic pathways both lead to activation of FX. FXa, FVa and Ca2+ 
activate prothrombin (FII) to form thrombin (FIIa). Thrombin has several actions: it 
activates fibrinogen (FI) to yield fibrin monomers; it amplifies the coagulation process by 
activating further prothrombin, FV and FVIII; it activates FXIII whose active form 
promotes cross-linking of fibrin monomers to form stable polymers; (as discussed later in 
the cell-based model, it also participates in processes that temper coagulation to avoid 
overwhelming pathological thrombosis.) The common pathway thus yields a mesh of 
covalently cross-linked fibrin strands and entrapped red blood cells, which form a stable 
blood clot. Disorders of the common pathway will affect tests of the intrinsic and extrinsic 
pathways. 
6. The cell-based model 
The five steps of this model are initiation, amplification, propagation, stabilisation and 
inhibition of further coagulation (7). In health, 1% of circulating FVII is in the active form. 
 
 
Blue, Red and Purple correspond respectively to Intrinsic, Extrinsic and Common Pathways of the 
Classic Coagulaton Cascade. Thrombin has a key role throughout, hence is shown in yellow. TF = 
Tissue Factor. vWF = von Willebrand Factor. TAFI = Thrombin Activated Thrombolysis Inhibitor. TFPI 
= Tissue Factor Pathway Inhibitor. 
Fig. 3. The Cell-Based Model of Coagulation 
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 At ‘initiation’, TF binds to circulating FVIIa and acts with FV to generate FIXa and FXa. 
The FXa converts a small amount of FII to thrombin.  
 During ‘amplification’ this thrombin triggers reactions on the surface of activated 
platelets, where more FVIIa is produced. Thrombin activates co-factors FV and FVIII. 
These active factors facilitate the sequence of thrombin-producing reactions.  
 In ‘propagation’, the TF/FVIIa complex continues to activate FIX and the FIXa/FVIIIa 
(“tenase”) complex generates more FXa to drive a continuous “thrombin burst”.  
 In ‘stabilisation’, FXIII is activated by high levels of thrombin and polymerises the fibrin 
monomers to complete the clot. Thrombin-activated Fibrinolysis Inhibitor contributes to 
clot stability. 
 Pathological thrombosis is prevented by regulation of the coagulation process. 
‘Inhibition of further coagulation’ occurs via activated protein C (aPC), protein S, tissue 
factor pathway inhibitor (TFPI) and antithrombin. Thrombin activates protein C, which 
cleaves FVa and FVIIIa with Protein S acting as a cofactor. TFPI binds TF/FVIIa and 
FXa in a quaternary complex. Antithrombin inhibits thrombin, FIXa and FXa. (8, 9) 
7. Platelet function in haemostasis 
Platelets respond to vascular wall damage by adhesion, aggregation, release of granule 
content and morphological changes. Von Willebrand Factor is a plasma protein that acts as a 
bridge between platelets and the exposed collagen of damaged tissue. The platelet binding 
site is the membrane glycoprotein GPIb-VIX. Von Willebrand Factor also acts as a carrier 
protein for, and stabiliser of FVIII, preventing premature proteolytic degradation by  
Protein C. 
8. Coagulation pathology 
Hypercoagulability / Thrombophilia 
A hypercoagulable state can predispose a patient to deep vein thrombosis (DVT), 
pulmonary embolism (PE), stroke, and recurrent miscarriage. Causes include disorders of 
platelets, vessel walls, systemic disease and well as genetic and environmental factors (10). 
Haemophiliae and other Bleeding Diatheses 
Disorders of coagulation factors tend to present with haemarthroses and muscle 
haematomas. Patients with platelet disorders more commonly present with skin bruising, 
epistaxis or menorrhagia. Von Willebrand’s Disease is the most common inherited 
coagulopathy; other forms are rare, apart from Haemophilia A and B. The most common 
acquired coagulation disorders are disseminated intravascular coagulation (DIC), liver 
disease and vitamin K deficiency although disorders discussed elsewhere in this chapter are 
more common in the setting of cardiac surgery. 
9. Anticoagulant drugs 
These drugs are used to prevent thrombus formation, or limit the extension of existing 
thrombus. Venous thrombus consists of a fibrin web with trapped platelets and erythrocytes 
and is more successfully treated or prevented with anticoagulants than arterial thrombus, 
which contains proportionally more platelets and less fibrin. 
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Source Hypercoagulable risk factor (mechanism and notes in brackets) 
Blood Protein S and Protein C deficiencies (these normally regulate 
coagulation) 
Polycythaemia rubra vera, Thrombocytosis (blood is more viscous 
thus prone to stasis – treatment may include bone marrow 
suppression)  
Paroxysmal Nocturnal Haemoglobinuria (excessive RBC sensitivity 
to complement) 
Prothrombin 20210 mutation (leads to increased prothrombin levels) 
Heparin Induced Thrombocytopenia (heparin-associated antibodies 
develop) 
Antithrombin III deficiency (incidence 1 in 5000) 
Inherited dysfibrinogenaemia (rare) 
Leiden Factor V mutation - the most common hereditary cause of 
hypercoagulable state (anticoagulant effect of activated protein C is 
ineffective against mutated factor V)  
Thalassaemia  
Sickle Cell Disease 
Systemic Pregnancy / postpartum 
Iatrogenic Oestrogen (increases coagulation factors and reduces 
anticoagulant effect of antithrombin III) 
Sepsis (increased circulating tissue factor) 
Hyperhomocysteinaemia (genetic disorder, treated with folate, 
vitamin B6 & vitamin B12) 
Smoking (mechanisms include endothelial damage and platelet 
adhesion) 
Congestive Heart Failure (mechanisms include vascular endothelial 
dysfunction & increased fibrinogen) 
Antiphospholipid syndrome, including lupus anticoagulant (either 
primary or secondary to infection, drugs, malignancy) 
Uraemia (endothelial dysfunction, increased cytokines) 
Surgery (reduced risk with thromboprophylactic drugs 
perioperatively) 
Diabetes mellitus (increased platelet activation) 
Hyperlipidaemia 
Obesity 
Malignancy (tumour cells activate clotting cascade and inhibit 
fibrinolysis) 
Trauma/burns (release of tissue thromboplastin) 
Immobility (blood stasis) 
Hyperthyroidism (increase in circulating FX) 
Hypothyroidism (increased circulating fibrinogen, FVII) 
 
 
Fig. 4. Causes of a Hypercoagulable State (11) 
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Inherited Bleeding Disorders Notes 
Von Willebrand Disease (vWD) Autosomal dominant, affects 1% of population. Von 
Willebrand Factor (vWF) can be deficient, defective or 
completely absent. vWF allows platelets to adhere to 
damaged endothelium and also stabilises circulating 
FVIII. Severe vWD can therefore cause FVIII deficiency. 
Desmopressin raises vWF in mild disease, in more severe 
disease FVIII/vWF concentrate may be required. 
Haemophilia A = FVIII deficiency Inherited, X-linked recessive (affecting males). Severe 
coagulation disorder. FVIII concentrate is given 
prophylactically in profound deficiency, and as required 
in milder forms of the disease. 
Haemophilia B = FIX deficiency Severe coagulation disorder, also X-linked, clinically 
indistinguishable from Haemophilia A. 
Thrombocytopenia May be due to primary bone marrow dysfunction, 
autoimmune disease, or a consequence of other disease 
processes or drugs. 
FXI deficiency Patients exhibit a variable bleeding disorder  
Factor V deficiency
Structural problems with blood 
vessels 
Disorders such as Haemorrhagic Telangiectasia and 
Ehlers-Danlos syndrome 
Acquired Bleeding Disorders Notes 
DIC Pathological activation of coagulation from triggers such 
as sepsis, malignancy, burns, or obstetric emergencies. 
Widespread microvascular thrombosis leads to 
consumption of clotting factors and platelets which is 
followed by bleeding. Increased Fibrin Degradation 
Products (FDPs) may also impair coagulation. High 
mortality, primarily from complications of microvascular 
thrombosis. Fresh frozen plasma and platelets are given 
whilst underlying trigger is addressed. 
Liver Disease Synthesis of coagulation factors is affected. Portal 
hypertension can also lead to splenomegaly with 
sequestration of platelets and resultant 
thrombocytopenia 
Vitamin K Deficiency Can occur with malabsorption of this fat-soluble vitamin 
in obstructive jaundice. Deficiency of FII, FVII, FIX, FX 
occurs 
Thrombocytopenia May be due to primary bone marrow dysfunction, 
autoimmune disease, or a consequence of other disease 
processes or drugs. 
Platelet dysfunction Disorders of platelet granules can occur in 
myelodysplastic disease, haematological malignancy, 
uraemia or liver disease. Antiplatelet drugs are also 
discussed in this chapter. 
HELLP syndrome A severe variant of preeclampsia characterised by 
Haemolysis, Elevated Liver enzymes, and Low Platelets 
Allergic purpura Inflammation of small blood vessels with leakage 
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10. Thrombin inhibitors 
Thrombin (FIIa) is central to the coagulation process. It usually converts soluble fibrinogen 
to fibrin, stimulates platelets and activates FV, FVIII, FXI and FXIII. Thrombin inhibitors can 
work directly on FIIa, or indirectly by preventing activation of FII.  
Heparin is long-established as an anticoagulant, which facilitates endogenous antithrombin 
to decrease activation of FII. The indirect mechanism has limited activity against thrombin 
that is bound to fibrin or fibrin degradation products (FDPs). In contrast, direct-acting 
thrombin inhibitors (DTIs) inhibit bound, as well as free, FIIa. 
Heparin remains the most widely used drug in this class, but other agents are being 
investigated that may offer increased efficacy or a more favourable side-effect profile. 
Thrombin inhibitors may also have administrative advantages over heparin if they can be 
given orally and if anticoagulation monitoring is unnecessary.  
Indirect thrombin inhibitors 
Heparin 
Heparin is found in the liver and mast cell granules. Commercial heparin is extracted from 
bovine or porcine sources and is a mixture of acid mucopolysaccharides with molecular 
weights ranging from 3000 to 60,000 daltons. It is available in this unfractionated form and 
also as various low-molecular weight preparations. Heparin reversibly binds to 
antithrombin III, thereby enhancing inhibition of FIX, FX, FXI, FXII, FXIII, thrombin and also 
plasmin. At high concentrations heparin also inhibits platelet aggregation. 
Unfractionated heparin is given intravenously or subcutaneously and is also used to 
anticoagulate the cardiopulmonary bypass circuit in cardiac surgery. Intravenous doses are 
titrated to a target range of ACT or APTT. The biological half-life is 1hr at physiological 
temperature but longer at lower temperatures during cardiopulmonary bypass. Heparin 
effects are reversed by protamine, a base that forms a stable, inactive salt complex with the 
acidic heparin. 
Low-molecular weight heparin preparations have an average molecular weight below 8000 
daltons. They are more effective at inhibiting factor Xa than unfractionated heparin, with 
less of an effect on thrombin. Their longer half-life and more predictable pharmacokinetic 
profile make them suitable for once-daily subcutaneous dosing without routine coagulation 
monitoring. APTT is not altered by LMWH so if monitoring is needed, anti-Xa levels are 
measured; this is useful for patients with renal impairment or at extremes of weight. LMWH 
effects cannot be reversed with protamine. 
Side-effects of heparin can include hyperkalaemia and Heparin-induced 
Thrombocytopaenia (HIT). HIT has a frequency of 2.6% when unfractionated heparin is 
used, and 0.2% with LMWH (12). The most severe form of HIT is immune-mediated and can 
be complicated by thrombosis. Platelet counts should therefore be monitored in patients 
receiving heparin. If HIT occurs, heparin should be discontinued and an alternative 
anticoagulant used to reduce the risk of thrombosis. Warfarin should not be given to 
patients with HIT because of the high risk of warfarin necrosis, so alternatives such as 
lepirudin or danaparoid are chosen. A screening test for antibodies is the initial 
investigation when HIT is suspected. Patients testing positive proceed to the more specific 
serotonin release assay. 
For post-CPB reversal of heparin, protamine sulphate is used. 1 mg of protamine neutralises 
the effect of 100 i.u of unfractionated heparin, by combining with heparin to form an 
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inactive salt compound. Protamine acts within 5 minutes and can last for 2 hours. Effective 
protamine reversal is confirmed when the ACT returns to the baseline value. 
Excess administration of protamine is undesirable, as it has its own intrinsic anticoagulant 
effect at high doses. It should be given slowly to minimise cardiovascular side-effects 
(systemic arterial vasodilatation and pulmonary arterial vasoconstriction), and the 
maximum administration rate in adults is 50mg per 10 minute period. 
Protamine can only partially reverse the anticoagulant effect of LMWH. 
Other indirect thrombin inhibitors 
Warfarin reduces hepatic synthesis of FII. Factor Xa inhibitors will reduce activation of FII. 
These agents are considered by some sources to be indirect thrombin inhibitors and are 
covered elsewhere in this chapter. 
Direct thrombin inhibitors  
This class includes Dabigatran, Argatroban, Bivalirudin, the recombinant Hirudins (eg 
lepirudin and desirudin) and also Melagatran and its prodrug Ximelagatran. 
Dabigatran is a direct thrombin inhibitor, taken orally, which is being increasingly used in 
prevention of thromboembolism following lower limb joint replacement surgery. 
Dabigatran is also gaining a role in prevention of embolic stroke in patients with atrial 
fibrillation. The predictable pharmacokinetic profile allows a fixed-dose regimen to be used 
without routine coagulation monitoring. Dabigatran cannot be reversed. It should be 
discontinued at least 24hrs before elective surgery. In the event of life-threatening 
haemorrhage, non-specific prohaemostatic agents such as recombinant factor VIIa and 
prothrombin concentrate complexes could be considered; accelerated clearance using 
haemofiltration or charcoal filtration has also been suggested (13). 
Argatroban is given intravenously and has a role in prevention/treatment of thrombosis 
and during Percutaneous Coronoary Interventions (PCI) in patients with HIT. It is 
metabolised hepatically so may be more appropriate than Lepirudin for patients with renal 
impairment. Its effect can be monitored by APTT. 
Hirudins are direct thrombin (FIIa) inhibitors derived from chemicals found in leech saliva. 
Lepirudin and Desirudin are recombinant agents. Lepirudin is used to anticoagulate 
patients with HIT. It is given intravenously, titrated according to APTT(14), and cleared 
renally. Desirudin can be given subcutaneously to prevent thromboembolism.  
Bivalirudin is a hirudin analogue, and can be used in combination with antiplatelet agents 
for patients undergoing percutaneous coronary intervention (PCI). It can be titrated 
according to ACT(14). Thrombin function recovers to normal approximately 1hr after 
Bivalirudin infusion is discontinued. 
Melagatran and its prodrug Ximelagatran were withdrawn from the market after the 
EXTEND trial found potential risk of severe liver injury (15). 
11. Factor Xa inhibitors 
The synthetic pentasaccharide Fondaparinux is an indirect FXa inhibitor, with structural 
similarities to heparin. It works by facilitating antithrombin III (AT) activity, and is therefore 
dependent on AT for its effect (16). Fondaparinux is given subcutaneously for 
prevention/treatment of venous thromboembolism, and for acute coronary syndrome. In 
patients with normal renal function, anticoagulation effects persist for 2-4 days after 
discontinuation of Fondaparinux. There is no antidote available to reverse the effect of 
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Fondaparinux. It does not affect PT, APTT or ACT. Although monitoring is not routinely 
required in healthy patients, it can be achieved by an anti-FXa assay.  
Newer orally-administered drugs Rivaroxiban and Apixaban are direct FXa inhibitors. They 
have similar indications to Fondaparinux. 
Heparinoids 
Danaparoid is produced from the same porcine material as heparin, but all heparin and 
heparin fragments are extracted. It catalyses AT-mediated inhibition of FXa and, to a lesser 
extent, FIIa (17). It has been used to anticoagulate patients with HIT. There can be cross-
reactivity so patients should continue to have platelet count monitored (18). Coagulation 
monitoring, if required, is by anti-Xa assay. It is not reversed by protamine. 
Warfarin 
This oral agent is used to minimise the risk of embolic stroke in patients with valvular heart 
disease or arrhythmia, and to prevent/treat venous thromboembolism. It inhibits the 
hepatic synthesis of vitamin K-dependent coagulation factors (FII, FVII, FIX, FX) as well as 
proteins C, S and Z (19). It takes at least 48hrs to develop the anticoagulant effect, during 
which time the inhibition of proteins C and S may paradoxically create a prothrombotic 
state, hence heparin is usually added during warfarin introduction. Warfarin effect is 
titrated using PT or INR tests with target ranges shown in the table. Additional or 
alternative agents may be recommended in valvular or structural heart disease (20). 
Perioperatively, warfarin is only continued for certain procedures with low risk of bleeding. 
Warfarin is usually held 5 days prior to surgery with INR ≤1.5 confirmed immediately pre-
op. A shorter-acting anticoagulant, such as LMWH, can be given as bridging anticoagulant 
therapy until shortly before surgery and continued once haemostasis has been obtained. The 
decreased risk of thrombosis or embolism by using bridging anticoagulation is weighed 
against the increased risk of haemorrhage. Decisions regarding perioperative 
anticoagulation are made on an individual patient basis (22). 
 
Warfarin Indication Target INR (+/- 0.5) 
Atrial fibrillation, DVT, PE 2.5 
Recurrent DVT/PE despite INR >2 3.5 
For Cardioversion in Atrial Fibrillation 3.0 for ≥ 3 weeks prior, and 2.5 for 
≥ 4 weeks post-Cardioversion 
Mechanical Prosthetic Heart Valves: 
Individualised targets based on: (a) thrombogenic 
risk of the valve type and position, (b) patient-
related risk factors for thrombosis and haemorrhage 
(20, 21). 
Typically 3 for aortic valves,  
3.5 for mitral valves. 
Bioprosthetic Valves 2.5 for 3 months post-insertion, 
after which consider 
discontinuation if no other risk 
factors 
INR = International Normalised Ratio, DVT = Deep Venous Thrombosis, PE = Pulmonary Embolism (22) 
Fig. 5. INR targets. 
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In the event of major haemorrhage in a patient who is anticoagulated with warfarin, it may 
be necessary to discontinue warfarin, administer vitamin K 5-10mg (phytomenadione), and 
in some cases replace the deficient coagulation factors using prothrombin complex 
concentrate 30-50 units/kg (containing FII, FVII, FIX, FX) or fresh frozen plasma 10-
15ml/kg. 
Antiplatelet agents 
These agents have a variety of mechanisms of action as shown in the table. Decisions 
regarding perioperative discontinuation of these medications are made on an individual 
patient basis. As with other anticoagulants, continuation increases perioperative bleeding 
but withholding the agent increases risk of thrombosis. The risk of withholding antiplatelet 
agents in the setting of acute coronary syndrome generally outweighs the benefits so they 
are usually continued in this context (23).  
Prostacyclins 
Epoprostenol is a prostacyclin that can be infused to treat pulmonary hypertension, or to 
inhibit platelet aggregation during renal dialysis. 
Antifibrinolytic Agents 
Aprotinin, tranexamic acid and aminocaproic acid are antifibrinolytic agents, which can be 
used to decrease peri-operative bleeding. Aprotinin is a naturally-occurring serine protease 
inhibitor, and the other two agents are lysine analogues. Studies have shown reduction in 
blood loss and transfusion requirements with the use of these agents, particularly in patients 
taking antiplatelet agents perioperatively (25, 26). 
Aprotinin was associated with increased incidence of death, cerebrovascular accidents and 
renal events in an observational study of patients undergoing revascularisation surgery (27). 
These effects were not seen with tranexamic acid or ε aminocaproic acid. Indeed a prior 
meta-analysis of aprotinin use in patients undergoing cardiopulmonary bypass suggested it 
was safe (28). The current recommendation is to reserve aprotinin use for patients at the 
highest risk of bleeding complications (29).  
12. Laboratory coagulation tests 
Platelet count 
The normal range is 150-400 x109 / L. Thrombocytopenia can occur as a result of decreased 
bone marrow production or excessive destruction. Typically, traumatic bleeding, purpura 
and easy bruising occur at platelet counts less than 50 x109/L; spontaneous bleeding may 
occur at platelet counts below 20x109/L. There is not a strong evidence base for a 
transfusion trigger in thrombocytopaenia (30), however the consensus is that a platelet 
count of >50 x109 should be achieved prior to invasive procedures (31) with a higher target 
of >100 x109 prior to neurosurgery. 
Platelet function 
Platelet function can be impaired by low pH, hypothermia, myeloproliferative disease, 
uraemia, non-steroidal anti-inflammatory drugs and antiplatelet drugs. As well as having a 
sufficient number of platelets, adequate platelet function is also necessary for haemostasis. 
Platelet function is not measured in standard laboratory tests, but it is possible to measure 
platelet activity using methods such as aggregometry. Platelet function can be inferred from  
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Antiplatelet Drug Name Mechanism of Action Implications for Cardiac 
Surgery 
Aspirin = Acetylsalicylic 
acid 
Prevents Thromboxane A2
production (by irreversibly 
acetylating cyclooxygenase-
1) therefore reducing 
platelet aggregation  
Antithrombotic effect starts 
within 30min of oral 
loading dose and lasts for 
lifespan of the platelet (8–10 
days). Is often continued 
perioperatively with some 
degree of platelet 
dysfunction expected. 
Thienopyridine 
derivatives: 
Clopidogrel, Ticlopidine, 
Prasugrel 
Their metabolites covalently 
bind to the P2Y12 receptor, 
the main platelet receptor 
responsible for ADP-
induced platelet 
aggregation.
Active within 2hrs of oral 
loading dose. Lower risk of 
GI-bleeding than aspirin. 
Expect platelet dysfunction 
if not discontinued at least 
7 days pre-operatively (23). 
Direct-acting P2Y12 
inhibitors: 
Cangrelor, Ticagrelor, 
Elinogrel 
These agents change P2Y12 
receptor conformation, 
causing a reversible, 
concentration-dependent 
receptor inhibition.
These are in phase 3 of 
development(24) 
Dipyridamole Inhibits phosphodiesterase, 
therefore increasing 
intraplatelet concentrations 
of cyclic AMP which 
reduces the activation of 
cytoplasmic second 
messengers. Also stimulates 
prostacyclin release and 
inhibits thromboxane 2A 
production
Short half-life so usually 
given as a slow-release 
preparation. 
Glycoprotein IIb/IIIa 
receptor antagonists: 
Abciximab, Tirofiban, 
Eptifibatide  
Compete with ligand 
binding of fibrinogen to 
glycoprotein IIb/IIIa 
receptor, therefore block the 
final common pathway for 
platelet aggregation. Given 
intravenously as loading 
bolus followed by infusion.  
Platelet function can take 2 
days to recover following 
discontinuation of 
Abciximab infusion. 
Strategies to reduce blood 
loss may include: 
1) Delaying surgery for 
12hrs post-abciximab, and 
2hrs post-tirofiban or 
eptifibatide. 
2) Platelet transfusion (less 
effective if given when free 
drug still in circulation) 
3) Fibrinogen or 
antifibrinolytics may be of 
benefit 
Fig. 6. Antiplatelet Agents, their mechanisms of action and implications for Cardiac Surgery 
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thromboelastography (see later section). Bearing in mind the lack of routine platelet function 
measurement prior to cardiac surgery, it is important to identify clinical clues to impaired 
platelet activity. A patient’s medication history should be noted. Some patients are advised 
to stop antiplatelet agents in advance of elective surgery. In those taking clopidogrel up to 
the day of surgery, platelet dysfunction should be anticipated as should the need for platelet 
transfusion. 
Prothrombin time (PT) and international normalized ratio (INR) 
Blood is sampled into a tube containing EDTA or citrate, both of which chelate calcium and 
prevent the blood clotting en route to the laboratory. The sample is centrifuged in the lab to 
yield platelet-poor plasma. The test starts when calcium and thromboplastin (consisting of 
tissue factor and phospholipid) are added to the plasma, and is complete when fibrin 
strands are formed. The time taken is the PT. The INR puts the measured PT in context by 
comparing it with the PT of a standardised plasma sample. An INR of 1.0 is normal; higher 
INRs represent coagulation that is impaired secondary to pathology or drugs. PT and INR 
are considered to be tests of the extrinsic pathway, with FVII deficiency having the greatest 
impact on raising the INR/PT. Other causes of abnormal PT and INR are shown in the table. 
Of note, the large amount of TF used to trigger coagulation in this test negates the effect of 
TFPI and renders the test independent of FVIII, FIX and FXI, meaning patients with 
haemophilia can have normal PT and INR results.  
Activated partial thromboplastin time (APTT) and aptt ratio (APTTR) 
The blood sample for this test is prepared in the same way as that for the PT. The resultant 
platelet-poor plasma is triggered to coagulate by mixing it with the APTT reagent and 
replacing the chelated calcium. The APTT reagent consists of phospholipid (as a substitute 
for the platelet membrane) and negatively-charged particles that cause contact activation. 
The time taken for fibrin strands to form is the APTT. The APTT ratio is calculated in a 
similar manner to the INR, with normal APTTR being 1.0 and higher values representing 
coagulopathy. APTT is prolonged by deficiencies of the Intrinsic or Common pathways, 
meaning any procoagulant factor deficiency apart from FVII and FXIII will prolong the  
 
Causes of Prolonged PT and INR Notes 
Decreased FVII  FVII deficiency has a greater impact on PT and 
INR than other factor deficiencies 
Decreased FI, FII, FV, FX  
Liver disease  Decreased factor (including fibrinogen) synthesis 
Vitamin K deficiency  Synthesis of FII, FVII, FIX, FX are vitamin K-
dependent 
Disseminated Intravascular 
Coagulation (DIC)  
Widespread factor depletion due to consumption 
High dose heparin  
Sample tube under-filled  Dilution artefact due to standard volume of 
citrate (or EDTA) mixing with lower volume of 
plasma 
Raised Haematocrit  Thus lower percentage volume of plasma, also 
leads to dilution artefact 
Fig. 7. Causes of Prolonged PT and INR 
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APTT. APTT is used to titrate unfractionated heparin anticoagulation. It is also a screening 
tool for Haemophilia A and B. Prolonged APTT does not necessarily predict clinical 
bleeding, for example FXII deficiency greatly prolongs APTT but is not associated with 
bleeding tendency. 
 
Causes of Prolonged APTT and APTTR Notes 
Procoagulant factor deficiency (except 
FVII or FXIII) 
FVII is not involved in the intrinsic pathway. 
Completion of the test does not require 
FXIII-dependent cross-linking of fibrin. 
Specific Clotting Factor Inhibitors eg. Factor VIII inhibitors develop in up to 
10% of patients with haemophilia A 
Contamination of sample with heparin Sample drawn from vein upstream of 
heparin infusion, or contaminated by 
heparin in the pressure-bag of an arterial line 
Lupus Anticoagulant This is a non-specific inhibitor of the intrinsic 
pathway so prolongs APTT. Paradoxically, 
patients with lupus anticoagulant actually 
have a prothrombotic tendency. 
Dilution artefact Underfilling of the sample tube, or raised 
haematocrit will increase the proportion of 
citrate (or EDTA) to plasma 
Thrombin clotting time (TT or TCT) and hemoclot® 
TT measures the time taken for fibrin to form when thrombin is added to the plasma 
sample. Prolongation of TT suggests low fibrinogen levels, dysfibrinogenaemia or inhibition 
of thrombin. Thrombin can be inhibited by unfractionated heparin or direct thrombin 
inhibitors. Fibrin degradation products inhibit fibrin cross-linking; at high concentrations 
these can also prolong the TT. 
Adding Protamine sulphate to the sample will negate the effect of heparin and FDPs. 
Adding Toluidine Blue will negate the effect of heparin but not FDPs. Another technique for 
samples containing heparin is to perform a “Reptilase Test”, where a snake venon product 
‘Reptilase’ is used to activate fibrinogen. Unlike thrombin, reptilase is not inhibited by 
heparin. 
Hemoclot® is a sensitive, diluted TT assay. 
These tests are used to assess the effectiveness of fibrinolytic therapy and may be useful in 
quantifying the effects of direct thrombin inhibitor drugs. 
Ecarin clotting time (ECT) 
This is a specific assay of thrombin generation. Ecarin comes from snake venom, and 
specifically activates prothrombin (FII). ECT can be used to monitor anticoagulation during 
Cardiopulmonary Bypass but is not widely utilised outside a research setting (13) 
Fibrinogen 
Fibrinogen (FI), the precursor of fibrin, is synthesised by hepatocytes and normal plasma 
concentration is 1.5-4.0g/L. Levels vary seasonally within an individual, and causes of 
abnormal fibrinogen level or function are shown in the tables below. Fibrinogen can be 
depleted by haemorrhage and consumed by coagulation during or after cardiac surgery, 
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and is routinely quantified by the Clauss method in this setting. The PT-derived fibrinogen 
level (PT-Fg) is more convenient but less reliable. When investigating congenital fibrinogen 
defects, more complex and time-consuming tests are employed. 
There is evidence that the low preoperative fibrinogen concentrations correlate with higher 
peri-operative blood loss in coronary artery bypass surgery (32, 33). Pre-operative 
prophylactic fibrinogen infusion may be beneficial, although larger trials are required to 
determine safety and efficacy of this practice (34). Pre-operative hyperfibrinogenaemia is 
associated with higher all-cause mortality (35), possibly because raised fibrinogen levels are 
a marker of inflammation, reflecting the presence of a systemic disorder (eg sepsis, acute 
coronary syndrome). 
In major blood loss treated with packed red blood cells and crystalloid/colloid intravascular 
volume resuscitation, fibrinogen is the first coagulation factor to become depleted (36). It is 
therefore a useful marker for severity of haemorrhage (37). 
Fibrinogen quality is assessed when thromboelastometry is performed in the presence of a 
platelet inhibitor, a test available commercially as “FIBTEM” (see ROTEM section). 
A prolonged Thrombin Time will also detect low fibrinogen levels.  
Options for replacing fibrinogen are fibrinogen concentrate reconstituted to 20g/L, Fresh 
Frozen Plasma containing 1.6-2g/L fibrinogen, or cryoprecipitate containing 17g/L. The 
traditional target of replacement of fibrinogen aimed for a level of 1g/L, but higher targets 
of 1.5-2g/L may be more appropriate in patients undergoing cardiac surgery (38).  
It remains to be established whether it is better to administer fibrinogen concentrate 
prophylactically, or to reserve treatment only for patients who are bleeding. There is also 
debate regarding the most suitable goal for fibrinogen replacement, which may be 
fibrinogen quantity (eg Clauss assay) or fibrin quality (eg. FIBTEM).  
The Clauss assay 
A high concentration of thrombin is added to diluted plasma and the clotting time is 
measured. A reference curve has been plotted using plasma of known fibrinogen 
concentrations. The fibrinogen concentration of the test sample is determined by comparing 
the clotting time with the reference curve. The clotting time can be determined 
automatically using systems that detect changes in light scattering, or light absorption as 
fibrin is formed. Artefacts can occur when turbid or lipaemic plasma causes abnormal light 
scattering, and when free haemoglobin or bile cause abnormal light absorption. Heparin will 
affect clot formation, making the Clauss assay inaccurate, so every effort should be made to 
obtain a heparin-free sample (avoid sampling within 4 hours of low-molecular weight 
heparin administration, caution when sampling from arterial lines flushed with heparin). If 
a heparin-free sample cannot be obtained (eg during Cardiopulmonary Bypass) then ion-
exchange resins or heparinase can be used to negate the heparin effect. Fibrin Degradation 
Products (FDPs) affect fibrinogen activity in vivo, and also affect the time taken to complete 
the Clauss assay, so this assay naturally reflects the any potential impact of FDPs. 
PT-derived fibrinogen assays (PT-Fg) 
This method indirectly measures fibrinogen by analysing the change in light scattering or 
optical density as fibrin is formed in the sample during the PT test. The advantage of this 
method is that it can give a measurement of fibrinogen any time the PT is tested without 
additional expense. The test may be inaccurate in samples with high fibrinogen and, of 
particular relevance to Cardiac Surgery, the test may be less reliable than Clauss in the 
investigation of bleeding diathesis. FDPs have less effect on the PT-Fg than on the Clauss  
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Causes of Elevated Plasma Fibrinogen 
Concentration 
Notes 
Increased age  
Female Sex  
Pregnancy and Oral Contraception  
Acute phase reaction  
Smoking  
Acute exercise  
Disseminated malignancy  
Seasonal change Higher fibrinogen levels in winter 
Genetic Polymorphism of the beta 
fibrinogen gene promoter (G-455A) 
Occurs in 20% of population, leads to 7-10% 
higher fibrinogen levels than GG genotype (39) 
 
Causes of Decreased Plasma 
Fibrinogen Concentration 
Notes 
Inherited Fibrinogen Defects (rare):  
 Congenital Afibrinogenaemia Grossly decreased fibrinogen synthesis, with low or 
undetectable plasma fibrinogen. Patients have 
haemorrhagic diathesis, prolonged clotting times 
and abnormal platelet function 
 Congenital Hypofibrinogenaemia Mild-to-moderate reduction in circulating fibrinogen 
levels. Potential for haemorrhagic problems, but 
patient may be asymptomatic.  
 Congenital Dysfibrinogenaemia  Immunoassays may detect fibrinogen, but tests that 
depend on production of fibrin strands will give 
lower fibrinogen results. Patients may have 
haemorrhagic tendency, thrombophilia or be 
asymptomatic 
Acquired hypofibrinogenaemia  
 Decompensated liver disease Hepatocellular failure leads to decreased fibrinogen 
synthesis. Excessive glycosylation of fibrinogen leads 
to an acquired dysfibrinogenaemia. Excess Fibrin 
Degradation Products (FDPs) also disrupt fibrinogen 
function. 
 Viral Hepatitis  
Disseminated Intravascular 
Coagulation (DIC) 
Generalised fibrin formation throughout the 
microcirculation leads to consumption and depletion 
of fibrinogen. FDP concentration is also raised.  
 Haemodilution From massive blood transfusion or fluid 
administration 
 Systemic Thrombolytic Therapy Usually leads to gross reduction in fibrinogen levels 
and high risk of haemorrhage 
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assay; an adequate fibrinogen measurement using PT-Fg may not reflect adequate 
fibrinogen activity if there is a significant quantity of FDPs in circulation. 
Clottable protein 
This test is too time-consuming and labour-intensive to be used routinely, but does give 
very accurate results and can be used for reference assays. 
Testing for specific coagulation factor abnormalities 
Clinical or laboratory evidence of abnormal coagulation that is not explained by 
haemorrhage, known pathology, or iatrogenic causes may require investigation of specific 
factor abnormalities. Uncommonly, individuals may have a factor deficiency or a factor 
inhibitor (the most common example is lupus anticoagulant). Consultation with a 
haematologist followed by specialised laboratory tests may be indicated. 
Other measurements in coagulopathy 
For effective coagulation, supportive management to maintain homeostasis is required. 
Temperature <34°C, pH <7.1, ionised Calcium <0.9mmol/L and Haematocrit <30% have all 
been shown to adversely affect haemostasis (40).  
In coagulopathy, hypocalcaemia should be corrected because of calcium’s key role in the 
activation of FX, FII, FXIII and Fibrinogen. Both haemodilution and chelation of serum calcium 
by citrate in units of packed red blood cells can contribute to hypocalcaemia in massive 
transfusion. A value for ionised Calcium can be rapidly obtained from many blood gas analysis 
machines, and the reference range is 1.0 – 1.3 mmol/L (no correction calculation required). Total 
Calcium ranges from 2.1 – 2.7mmol/L (corrected for hypoalbuminaemia may be necessary). 
Prevention of heat loss and active warming may be required to raise core temperature, 
acidotic patients may benefit from buffering, and haematocrit should be maintained with 
transfusion to optimise coagulation. 
When transfusing Packed Red Cells it is preferable to use blood that has been stored for the 
minimum possible duration, ideally less than two weeks. Transfusion of older blood has 
been associated with greater incidence of complications and higher mortality (41). 
13. Near patient coagulation tests 
ACT and TEG are the two most common Near Patient Tests (NPT) used in cardiac surgery. The 
main value of NPT is the short turn-around time, which gives feedback to the treating 
physician/surgeon without delay. An ACT reading can be obtained generally within 4 minutes 
of test initialisation, and a TEG within 10 to 15 minutes. A conventional coagulation screen 
generally has a turn-around time of 30 minutes, during which time one or more interventions 
may already have taken place, making the result less valuable and potentially obsolete. 
ACT (Activated Clotting Time) 
This is generally performed at the bedside or in the operating room by a perfusionist or 
doctor who is actively managing the patient. A pre-heparin baseline value is obtained to 
assist interpretation of subsequent results. Anticoagulation whilst on cardiopulmonary 
bypass (CPB) is usually guided by ACT, and the test is also used to assess success of 
protamine reversal of heparin when CPB is over. After Protamine, an ACT that is prolonged 
beyond the baseline value suggests heparin reversal may be incomplete, but it offers no 
information regarding other potential causes of coagulopathy. 
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14. Thromboelastography 
Thromboelastography was first described in 1948. Viscoelastic changes during coagulation 
are plotted against time(42). The abbreviation ‘TEG’ was used for this technique. TEG® is 
now a trademark for one manufacturer of thromboelastograph device, an alternative 
manufacturer uses the trademark ROTEM®. The principles are similar, described below.  
15. The principles of the thromboelastography (TEG) 
Samples for analysis are stored in a citrated tube and must be analysed within 4 hours. 
Kaolin (a clotting factor) is added to two separate cuvettes both containing sufficient 
calcium chloride to reverse the effect of the citrate. One of the cuvettes also contains a 
surface coating of heparinase to deactivate any heparin in the sample. Both cuvettes are 
loaded onto the analyser for simultaneous analysis.  
Each cuvette sits on a platform that oscillates through an angle of 4045´. The whole cycle 
lasts ten seconds including a 1 second rest period. A pin is freely suspended within the 
blood and is attached to a torsion wire which in turn is attached to a mechanical-electrical 
transducer. As the blood starts to clot within the cuvette, fibrin strands form between the 
blood and the pin and the torque is transmitted via the transducer to give a signal that is 
recorded by a computer (See figure 8).  
The variables that are recorded are as follows: “r” (reaction time) is the period of time, in 
minutes, taken to form the initial fibrin strands after placement of blood in the TEG analyser.  
 
 
Fig. 8. This image represents the TEG diagrammatically. (A) Shows a cross-sectional view of 
the apparatus. (B) Demonstrates the construction of the curve. (C) Shows the final printout 
of the TEG 
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Before this happens, the liquid blood in the cuvette exerts very little torque on the pin and 
the signal remains effectively zero (see figure 8). It is prolonged by congenital or acquired 
deficiencies in hepatic coagulation factors and anticoagulants such as unfractionated 
heparin, the low molecular weight heparins and warfarin. The “K” (K time) is the time, in 
minutes, after clot formation begins and the clot itself is of sufficient strength to produce a 
20mm divergence of the line. This reflects the speed of clot strengthening. The “K” is 
reduced by an elevated fibrinogen and by effective platelet function and is prolonged by the 
same factors that prolong the “r”. The “α” (alpha angle), measured in degrees, is the slope of 
the TEG tracing with respect to the r line (the line drawn between r1 and r2). It reflects the 
speed at which the clot is formed and behaves very much like the “K”. If the “K” is undefined 
(i.e. the signal generated by the computer never reaches an amplitude of 20mm) such as in 
hypocoaguable states then the “α” becomes more important. The “MA” (maximum 
amplitude) is a measure of the maximum strength developed by the clot. It is dependent on 
fibrin formation and platelet function. Percentage clot lysis is estimated at 30 (LY30) minutes 
or 60 (LY60) minutes after the “MA” is reached. The percentages are calculated by using the 
following formula: LY30 = (MA - A30)/MA ×100 and LY60 = (MA – A60)/MA × 100, where A30 
is the amplitude of the trace 30 minutes after “MA” is reached and A60 the corresponding value 
after 60 minutes. If the LY30 or LY60 are high then fibrinolysis is high. Finally, “C.I.” 
(coagulation index) can also be derived from “r”, “K”, “α” and “MA”by substitution into the 
following equation: C.I. = 0.3258r – 0.1886K + 0.1224MA + 0.0759α – 7.7922. This equation has 
been derived after multiple regression of a large database of TEG tracings. The “C.I.” reflects 
the patient’s overall coagulation state and normal values range from – 3.0 to + 3.0 (43).  
Platelet mapping with TEG 
Platelet mapping studies measure the degree to which a patient’s platelets can be activated by 
stimulation of either the thromboxane A2 (Txa2) receptor or the adenosine diphosphate (ADP) 
receptor. These receptors can be inhibited by aspirin and clopidogrel respectively, but the 
degree of inhibition varies between individuals. Thrombin activates platelets independent of 
the arachidonic acid and ADP receptors via the glycoprotein IIb/IIIa receptor.  
In cardiac surgery, antiplatelet agents are often withheld to minimise bleeding 
complications, which can expose patients to increased risks of peri-operative myocardial 
ischaemia. Platelet mapping may have a role in determining the optimum time to operate, 
such that antiplatelet agents are withheld for long enough to decrease the bleeding risk, but 
no longer than necessary. In the medical management of coronary artery disease, this 
technique could potentially be used before antiplatelet therapy is commenced, to determine 
which antiplatelet agent is likely to be effective for an individual patient. It might also be 
used after antiplatelet therapy has been initiated to measure the response to therapy. 
Platelet mapping can be assessed by the following method: 4 TEG channels (cups) are 
required. Cup 1 contains blood and kaolin (this activates the clotting cascade ex vivo) and 
the MA reflects thrombin activated platelets (MAthrombin). Thrombin in the blood sample is 
produced by trauma during the blood sampling procedure. Since the direct effect of 
thrombin on the IIb/IIIa receptor is not dependent on stimulation of either the Txa2 or ADP 
receptors, MAthrombin is an indirect measure of platelet function even in the presence of 
aspirin or clopidogrel. In all other 3 cups heparin is added to inhibit thrombin thus 
eliminating its direct action on the IIb/IIIa receptor. To the second cup 10μL reptilase and 
activated factor XIII (Activator F) is added which convert fibrinogen to fibrin by generating 
a cross-linked fibrin clot thus isolating the contribution of fibrin to the clot strength. 
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Activator F has no effect on platelets so the “MA” reflects the action of fibrin only (MAfibrin) 
(44). To the third cup 10μL Activator F and 10μL arachidonic acid (AA) are added and the 
MAAA reflects platelet responsiveness to AA. To the fourth cup 10μL Activator F and 10μL 
ADP are added and the MAADP reflects platelet responsiveness to ADP. The relative 
response of platelets to either AA or ADP is calculated as follows with a normal reference 
value for each being above 80%: 
Relative response of platelets to AA = (MAAA - MAfibrin) / (MAthrombin - MAfibrin) × 100.  
Relative response of platelets to ADP = (MAADP - MAfibrin) / (MAthrombin - MAfibrin) × 100. 
The platelet inhibition in response to an agonist is calculated by subtracting the percentage 
aggregation from 100 (45).  
Rotational Thromboelastometry (ROTEM®)  
ROTEM is based on the same principles as thromboelastography. Citrated whole blood is 
mixed with reagents in a stationary cuvette, then a pin is placed vertically into the blood and 
alternating clockwise and anticlockwise forces are applied to the pin. As the blood clots the 
pin’s oscillation is impeded, and when fibrinolysis occurs the pin will move more freely. 
The device records the changes in oscillation against time, creating the ‘thromboelastogram’ 
(TEM). The zero line indicates free movement of the pin. An amplitude of 100mm would 
indicate no movement of the pin, meaning the clot has reached the maximum possible 
firmness measurable by ROTEM. Combinations of reagents can be used to produce a series 
of TEMs that measure different aspects of the coagulation and fibrinolysis processes. 
The ROTEM machine has four channels, thus four TEMs can be generated simultaneously. 
By using combinations of coagulation triggers and coagulation inhibitors, a clearer 
understanding of the coagulation abnormalities can be obtained. The reference ranges for 
the parameters are not interchangeable between the different types of TEM, for example the 
MCF seen in the FIBTEM test will be significantly lower than that in INTEM or EXTEM, 
because clot firmness is due to the effect of fibrin only. 
Parameters measured using the ROTEM are as follows: 
 
ROTEM Parameter 
[Measured Variable]
Significance Clinical Application 
Clotting time (CT) 
 
[Delay from the start of the 
reaction to the start of clot 
formation. 
An amplitude of 2mm is 
taken to signify the start of 
clot formation.] 
This represents:
- the initiation of clotting 
- thrombin formation 
- the start of clot polymerisation 
Although not linearly related, CT is 
related to the PT for EXTEM, and 
the APTT for INTEM. 
Abnormalities that prolong the 
laboratory tests will prolong the CT 
in the comparable ROTEM test, but 
the endpoint for the laboratory test 
is fibrin formation, whereas in 
ROTEM a degree of fibrin 
stabilisation is required to attain 
2mm amplitude. 
Prolonged CT suggests 
anticoagulant drug activity or 
coagulation factor 
abnormalities. 
Consider: 
- Anticoagulant inhibitors such 
as protamine. 
- Replacement of coagulation 
factors (eg. specific factor 
concentrates, or fresh frozen 
plasma) 
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ROTEM Parameter 
[Measured Variable] 
Significance Clinical Application 
Clot Formation Time 
(CFT)  
 
[Delay from start of the 
reaction (2mm) to 
formation of a 20mm clot.]
CFT represents fibrin 
polymerisation, and stabilisation of 
the clot by activated platelets and 
FXIII. 
Prolonged CFT signifies a 
hypocoagulable state, and a short 
CFT corresponds with a 
hypercoagulable state. 
Prolonged CFT may represent: 
- deficiency of platelet quantity 
or function 
- low fibrinogen level 
- deficiency of fibrin 
polymerisation 
Consider: 
- fibrinogen replacement 
(fibrinogen concentrate, 
cryoprecipitate, fresh frozen 
plasma) 
- platelet transfusion 
Alpha(α)-angle 
 
[Angle formed between 
the x axis and a line that 
forms a tangent with the 
temogram curve and 
crosses the x axis at the 
point where clotting starts 
(2mm)] 
This describes the kinetics of 
clotting. 
A reduced -angle will correspond 
with a prolonged CFT. Increased -
angle will be seen in a 
hypercoagulable state. 
Reduced angle indicates a 
hypocoagulable state, consider 
the same causes and 
management as described for 
CFT. 
A (x) values 
 
[This is the amplitude at 
time x after the clot has 
started to form. (eg the 
A10 value is the amplitude 
at 10 minutes after CT)]
Low values are caused by the same 
abnormalities that prolong CFT and 
decrease the -angle (platelets, 
fibrinogen, FXIII) 
Reduced A (x) Values indicate a 
hypocoagulable state, consider 
the same causes and 
management as described for 
CFT. 
Maximum Clot Firmness 
(MCF)  
 
[The peak amplitude of the 
Temogram] 
Low MCF indicates a soft clot with 
potential for haemorrhage. 
Inadequate clot quality can reflect 
an abnormality of platelets, 
fibrinogen or FXIII. 
It can also be caused by 
hyperfibrinolysis. 
High MCF suggests a 
hypercoagulable state.
With low MCF:
- exclude hyperfibrinolysis 
- consider supplementing 
fibrinogen and/or platelets 
Lysis Index at 30 minutes 
(LI30)  
 
[The amplitude 30 minutes 
after CT, given as a 
percentage of MCF (the % 
remaining clot firmness) 
(LI45 and LI60 can be used 
to quantify late 
fibrinolysis)] 
In health, the high concentration of 
fibrinolysis inhibitors means there 
is negligible fibrinolysis and LI30 
should be close to 100% 
An abnormally low LI30 usually 
indicates hyperfibrinolysis, so 
antifibrinolytic drugs should be 
considered. 
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ROTEM Parameter 
[Measured Variable] 
Significance Clinical Application 
Maximum Lysis (ML)
 
[The decrease in 
amplitude (relative to the 
peak at MCF) that has 
occurred by the end of the 
measurement period given 
as a percentage of MCF. 
This is the % clot firmness 
lost.]  
This value represents the inverse of 
LI (% remaining clot firmness + % 
clot firmness lost = 100%) 
This value will increase if an 
extended measurement period is 
used. 
An abnormally high ML usually 
indicates hyperfibrinolysis, so 
antifibrinolytic drugs should be 
considered. 
 
 
[Reproduced with permission of Tem International GmbH] 
Fig. 9. ROTEM graph and basic parameters (a graph of an unstable clot has been chosen to 
enable illustration of the lysis parameters)  
 
The available ROTEM tests are described below: 
 
Name of Test 
[Test description] 
Relevant Parameters 
[Considerations if parameters are abnormal ] 
INTEM 
[Mild intrinsic coagulation 
pathway activation] 
CT [Factor deficiency (intrinsic pathway); Anticoagulant 
effects (heparin, thrombin inhibitors)] 
MCF, A(x), CFT, -angle [Platelet contribution to clot 
firmness; Fibrinogen concentration; Fibrin 
polymerisation] 
ML, LI(x) [Hyperfibrinolysis] 
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Name of Test 
[Test description] 
Relevant Parameters 
[Considerations if parameters are abnormal ] 
MCF, A(x), ML, LI(x) [FXIII deficiency] 
HEPTEM 
[Mild intrinsic pathway 
activation. Heparinase added to 
degrade any heparin present in 
the sample.] 
If abnormal values seen on INTEM are corrected in the 
HEPTEM graph, these effects are attributable to heparin. 
EXTEM 
[Mild extrinsic pathway 
activation] 
CT [Factor deficiency (extrinsic pathway)] 
MCF, A(x), CFT, -angle [Platelet contribution to clot 
firmness; Fibrinogen concentration; Fibrin 
polymerisation] 
ML, LI(x) [Hyperfibrinolysis] 
MCF, A(x), ML, LI(x) [FXIII deficiency] 
FIBTEM 
[Mild extrinsic pathway 
activation. Platelet inhibitor 
(cytochalasin D) added, 
therefore the TEM represents 
only the fibrin component of the 
clot.] 
MCF, A(x), CFT, -angle [Fibrinogen concentration and 
Fibrin polymerisation] 
ML, LI(x) [Hyperfibrinolysis] 
MCF, A(x), ML, LI(x) [FXIII deficiency] 
When compared with EXTEM, FIBTEM gives an indirect 
evaluation of the platelet contribution to clot 
APTEM 
[Mild extrinsic pathway 
activator. Fibrinolysis inhibitor 
(aprotinin) ] 
If abnormalities of EXTEM are corrected on APTEM they 
are attributable to hyperfibrinolysis and may be 
correctable with antifibrinolytic drugs. 
 
A suitable combination of TEMs for a patient undergoing cardiac surgery would be INTEM, 
FIBTEM and HEPTEM. The INTEM is performed to look at CT (prolonged in consumptive 
coagulopathy and the heparin effect on the intrinsic pathway) and also the α-angle and MCF 
(to assess whether fibrinogen or platelet supplementation is needed). The HEPTEM is 
compared with INTEM to determine the degree of Heparin effect. FIBTEM is performed to 
define the fibrinogen contribution to the haemostatic plug. 
As recommended at the European ROTEM meeting 2007, a minimum of 3 sets of ROTEM 
should be performed; a baseline, a set whilst on CPB, and one after CPB. Further sets are to 
be performed if the patient is still bleeding. These tests can be performed quickly and 
interpreted safely between 10-15 minutes from the start of the tests. 
The FIBTEM test is used clinically to guide administration of fibrinogen (46), but evidence 
for the treatment trigger or therapeutic target has not been conclusively established. It has 
been suggested that a FIBTEM MCF of 7mm is adequate for haemostasis in orthopaedic 
surgery, but a higher target of 22mm has been discussed for cardiac surgery. 
Caveats for ROTEM use: 
The INTEM and EXTEM are not very sensitive to mild coagulation factor deficiencies, and 
are insensitive to defects of primary haemostasis (platelet aggregation). The EXTEM test 
may still be normal when INR is as high as 4, and may show pathological values with very 
high heparin levels. 
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Thromboelastography (TEG) versus Rotational Thromboelastometry (ROTEM) 
As discussed above, the techniques have a common origin. Both systems generate graphs of 
clot firmness between a cuvette and pin versus time. In the TEG system the cuvette oscillates 
around a pin throughout the clotting process, whilst in the ROTEM system the cuvette is 
fixed and the pin rotates.  
By convention, the parameters obtained from the graphs have been given different names in 
the two tests. A comparison of the nomenclature is given in the table below from an article 
by Luddington (42).  
 
 
Copyright of Clinical & Laboratory Haematology is the property of Blackwell Publishing Limited and 
its contents may not be copied or emailed to multiple sites or posted to a listserv without the copyright 
holder’s express written permission. However, users may print, download, or email articles for 
individual use. 
Fig. 10. Nomenclature of TEG and ROTEM 
Clinical application of near patient test results and evidence base for decision-making 
There are several studies in the literature that highlight the usefulness of the TEG in 
cardiac surgery. Shore-Lesserson et al demonstrated in a prospective randomized 
controlled trial of high risk cardiac surgical patients (n=105) that fewer patients 
randomized to the TEG arm were transfused fresh frozen plasma (p < 0.002) or platelets 
(p < 0.05) compared to those patients managed by standard coagulation tests in the post-
operative period (47). Total blood product transfusion was less in the TEG arm and this 
reached statistical significance. TEG was used to guide protamine, platelet, FFP and 
antifibrinolytic therapy. The authors concluded that TEG –based transfusion algorithm 
reduced transfusion requirements. 
Spiess et al assessed the usefulness of TEG in predicting postoperative haemorrhage and 
need for reoperation. They found that TEG was a better predictor (87% accuracy) than 
coagulation profile (51%) or activated clotting time (30%) (48). Another study by the same 
author concluded that costs and risks associated with allogenic blood transfusions could be 
reduced with the introduction of a TEG based haemostasis protocol in cardiac surgery (49). 
Tuman found that TEG predicted postoperative haemorrhage more accurately than routine 
coagulation tests (88% versus 33% respectively) (50). 
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Avidan et al (51) showed in a prospective randomised comparison trial that following 
algorithms based on point of care tests or on structured clinical practice with standard 
laboratory tests did not decrease blood loss, but did reduce the transfusion of all blood 
components (p < 0.05) after routine cardiac surgery, when compared with clinician 
discretion. 
Finally, Westbrook et al showed in a prospective randomised controlled study a non-
statistically significant trend toward less blood product usage in a strict protocol utilizing 
TEG compared to physician’s choice based on clinical experience and standard laboratory 
coagulation tests. The study also demonstrated a cost saving benefit (52). 
Use of an automated protamine titration system, such as the commercially available point-
of-care Hepcon®, has been shown to be associated with higher heparin and lower 
protamine doses. This can potentially decrease activation of the coagulation and 
inflammatory cascades, with possible advantages of decreased postoperative bleeding and 
blood product requirement.(23)  
Blood product administration in cardiac surgery and the cardiothoracic ICU 
If a patient bleeds in the postoperative period, it is important to distinguish between 
‘surgical’ and ‘medical’ bleeding. A ‘medical bleed’ from the microvasculature occurs due to 
a coagulation abnormality, and this abnormality must be detected and corrected with blood 
products or pharmacological agents to halt the bleeding. In contrast a ‘surgical bleed’ is 
from a cardiac or large vessel injury and will often require resternotomy to re-establish 
haemostasis surgically. Misdiagnosis of ‘surgical bleeding’ can lead to unnecessary 
resternotomy, whilst failure to diagnose a ‘surgical bleed’ may lead to delay and futile use of 
blood products. A progressive, untreated ‘surgical bleed’ will lead to a combined ‘medical’ 
AND ‘surgical’ bleed. Likewise, a ‘medical bleed’ that is not correctly treated may result in a 
pericardial tamponade that needs surgical intervention. 
Factors to be considered in post-operative haemorrhage include: 
-  Complexity of surgery and adequacy of surgical haemostasis at end of operation 
- Baseline coagulation status (APTT, PT, platelet count, ACT or TEG) compared with 
post-operative measurements 
- Anticoagulation therapy pre-operatively (Antiplatelet therapy, Warfarin, Heparins, FXa 
or thrombin inhibitors) 
- Intraoperative blood loss and blood product replacement 
- CPB duration 
- Intra-operative anticoagulant use and reversal 
- Pump blood usage (this contains additional heparin, thus may require further 
protamine reversal). 
- Core temperature 
- Blood pH 
- Ionised calcium level 
Where possible, administration of blood products should be minimised(53). With donor 
screening and testing of donated blood, the risk of blood-borne disease transmission has 
decreased. Uncertainties regarding prion-related disease transmission remain, and there is 
also evidence that blood transfusion during cardiac procedures is associated with worse 
short- and long-term outcomes (41, 54). The measures below are adapted from the 2011 
Blood Conservation Clinical Guidelines published by the Society of Thoracic Surgeons and 
the Society of Cardiovascular Anaesthesiologists.(55)  
www.intechopen.com
 
Perioperative Considerations in Cardiac Surgery 204 
General Measures for Blood Conservation 
 If allogenic transfusion required, use leukodepleted red blood cells. 
 Routine blood salvage with centrifugation is useful. Intra-op autotransfusion, either 
direct or following centrifugation is useful  
 Blood salvage may be considered in malignancy, as the risk may be less than that 
associated with allogenic blood transfusion. 
 Multidisciplinary blood management teams can limit transfusion and peri-operative 
bleeding whilst maintaining safe outcomes. 
 Minimise volume taken for blood sampling 
 Do not transfuse if Hb≥10g/dL unless specifically indicated 
 Non-red cell haemostatic products ideally guided by point-of-care tests 
 DDAVP (Desmopressin) considered if platelet dysfunction likely to respond (eg 
uraemia, type I von Willebrand’s Disease) 
 Consider FIX in Haemophilia B 
Pre-op Measures 
 Identify high risk patients and utilise all available measures to conserve blood in this 
setting (ie. increased age, pre-op anaemia, small body size, non-CABG or urgent 
surgery, pre-op antithrombotic drugs, acquired/congenital clotting abnormality, 
multiple comorbidities, thrombocytopenia or abnormal platelet function) 
 Erythropoietin (EPO) and iron to correct anaemia, or for patients at high risk of 
developing anaemia 
 If possible, stop platelet P2Y12 inhibitors [thienopyridine pro-drugs (ticlopidine, 
clopidogrel, prasugrel), direct-acting P2Y12 inhibitors (cangrelor, ticagrelor)] and 
delay surgery until effect has subsided  
 Point-of-care testing of ADP-responsiveness may identify clopidogrel-non-
responders who do not require delay  
Intra-op Measures 
Medical 
 Lysine analogues (E-aminocaproic acid, tranexamic acid) reduce blood loss. 
 Risk/benefit ratio does not favour aprotinin use in adults 
Perfusion 
 Post-CPB pump salvage with reinfusion of pump blood is reasonable. Centrifugation 
is reasonable. Modified ultrafiltration is indicated. 
 Mini-CPB-circuits, vacuum-assisted venous drainage and retrograde autologous CPB 
circuit priming may reduce transfusion requirements. 
 Microplegia may reduce haemodilution associated with larger volumes of crystalloid 
cardioplegia solution 
 During CPB with moderate hypothermia, Hb≥6g/dL may be adequate, but higher 
transfusion trigger may be appropriate for patients at greater risk of critical non-
cardiac end-organ ischaemia 
 Open venous reservoir membrane oxygenator systems during CPB may decrease 
blood loss and improve safety 
 If CPB ≥2hrs, higher and/or patient-specific heparin concentrations may reduce 
consumption of platelets and coagulation factors 
 Protamine titration or empiric low-dose regimen post-CPB may decrease blood loss 
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Blood Products 
 Use safer fractionated products if possible, but plasma transfusion reasonable if 
multiple factor deficiencies and serious bleeding 
 Prothrombin Concentrate Complex (PCC) preferable to plasma for warfarin reversal 
provided PCC contains adequate FVII 
 Plasma transfusion considered as part of massive transfusion algorithm. 
 Intra-op platelet plasmapheresis for platelet salvage considered in high risk patients 
 Antithrombin III (AT) concentrate considered in patients with AT-mediated heparin 
resistance pre-CPB 
Surgical 
 TEVAR (thoracic endovascular aortic repair) may reduce blood loss compared with 
open procedure 
 Off-pump CABG may reduce blood loss compared with CPB approach 
 Topical haemostatic devices to aid anastomotic closure and topical antifibrinolytic 
agents may decrease blood loss. 
Post-op Measures 
 Routine dual antiplatelet therapy not indicated – only for patients with acute 
coronary syndrome or recent drug-eluting coronary artery stents 
 Consider FXIII for clot stabilisation if bleeding persists despite routine blood 
conservation measures 
 Consider FVIIa for intractable non-surgical bleeding unresponsive to routine 
haemostatic management  
 Mediastinal shed blood reinfusion, following washing and centrifugation, can be 
considered (direct reinfusion not recommended) 
 Therapeutic PEEP trial to decrease post-op bleeding is not well established 
 
Choice of fluid for intravascular volume replacement can also affect coagulation. Colloidal 
plasma substitutes may interfere with haemostasis in non-specific or specific ways. Non-
specific effects relate to haemodilution, with decreased circulating concentrations of 
coagulation factors, platelets and red blood cells. Specific effects are discussed by colloid 
type. 
Albumin inhibits platelet aggregation directly (56), and may affect fibrin polymerisation, but 
in vitro is considered not to affect haemostasis (57). 
Dextrans are not widely used due to potential allergic, renal and haemostatic side effects. 
They cause platelet dysfunction by decreasing vWF, possibly by adsorption. Dextrans also 
accelerate activation of fibrinogen, facilitate fibrinolysis, and may coat endothelium and 
platelets thus decreasing platelet adhesion. 
Gelatins can impair platelet coagulation (58) and decrease vWF, but are generally accepted 
not to influence perioperative bleeding (57). 
Hydroxyethyl starches (HES) induce platelet dysfunction through effects on GPIIb-IIIa 
expression and on vWF and FVIII levels. HES can also favour fibrinolysis. Haemorrhagic 
complications have been reported more frequently with high molecular weight (Mw) HES 
than with lower Mw. 
Use of colloids outside the context of clinical studies has recently been questioned as well 
(59). When using crystalloid alternatives, a balanced salt solution may offer less disruption 
of haemostasis than saline, possibly due to maintenance of plasma calcium concentrations. 
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16. Conclusion 
Perioperative management of coagulation needs to be tailored to the needs of the individual 
patient and delivered within the available resources of the Cardiac Surgery Centre. 
Appropriate use of medication and blood products can minimise perioperative thrombosis 
and bleeding, limit exposure to potentially harmful blood products and thus maximise 
quality of patient care.  
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